HomeCompareEPIX vs QYLD

EPIX vs QYLD: Dividend Comparison 2026

EPIX yields 840.47% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPIX wins by $4215412.26M in total portfolio value
10 years
EPIX
EPIX
● Live price
840.47%
Share price
$0.20
Annual div
$1.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4215412.28M
Annual income
$3,415,908,279,597.25
Full EPIX calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — EPIX vs QYLD

📍 EPIX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPIXQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPIX + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPIX pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPIX
Annual income on $10K today (after 15% tax)
$71,440.13/yr
After 10yr DRIP, annual income (after tax)
$2,903,522,037,657.66/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, EPIX beats the other by $2,903,522,032,847.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPIX + QYLD for your $10,000?

EPIX: 50%QYLD: 50%
100% QYLD50/50100% EPIX
Portfolio after 10yr
$2107706.15M
Annual income
$1,707,954,142,628.28/yr
Blended yield
81.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPIX right now

EPIX
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Price Target
$9.50
+4621.7% upside vs current
Range: $2.00 — $17.00
Altman Z
1.1
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPIX buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPIXQYLD
Forward yield840.47%11.92%
Annual dividend / share$1.69$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4215412.28M$25.4K
Annual income after 10y$3,415,908,279,597.25$5,659.31
Total dividends collected$4152700.41M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: EPIX vs QYLD ($10,000, DRIP)

YearEPIX PortfolioEPIX Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$94,747$84,047.22$10,352$1,192.36+$84.4KEPIX
2$845,608$744,228.02$10,830$1,347.57+$834.8KEPIX
3$7,112,413$6,207,612.95$11,460$1,539.07+$7.10MEPIX
4$56,406,815$48,796,533.54$12,275$1,777.84+$56.39MEPIX
5$422,031,389$361,676,096.60$13,323$2,078.95+$422.02MEPIX
6$2,980,575,750$2,529,002,163.86$14,667$2,463.34+$2980.56MEPIX
7$19,881,694,862$16,692,478,809.61$16,396$2,960.57+$19881.68MEPIX
8$125,334,964,899$104,061,551,396.31$18,631$3,612.97+$125334.95MEPIX
9$747,200,001,618$613,091,589,175.98$21,548$4,482.15+$747199.98MEPIX
10$4,215,412,281,328$3,415,908,279,597.25$25,398$5,659.31+$4215412.26MEPIX

EPIX vs QYLD: Complete Analysis 2026

EPIXStock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Full EPIX Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this EPIX vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPIX vs SCHDEPIX vs JEPIEPIX vs OEPIX vs KOEPIX vs MAINEPIX vs XYLDEPIX vs JEPQEPIX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.